Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy

Khan, Muhammad1,2; Zhao, Zhihong3; Arooj, Sumbal1,4; Fu, Yuxiang1; Liao, Guixiang1

2020-11-19

10.3389/fimmu.2020.587460

Frontiers in Immunology   影响因子和分区

1664-3224

Programmed death protein 1 (PD-1) interaction with PD-L1 deliver immunosuppressive environment for tumor growth, and its blockade with directed monoclonal antibodies (anti-PD-1/anti-PD-L1) has shown remarkable clinical outcome. Lately, their soluble counterparts, sPD-1 and sPD-L1, have been detected in plasma, and elevated levels have been associated with advanced disease, clinical stages, and worst prognosis for cancer patients. Elevated plasma levels of sPD-L1 have been correlated with worst prognosis in several studies and has displayed a persistent outlook. On the other hand, sPD-1 levels have been inconsistent in their predictive and prognostic ability. Pretherapeutic higher sPD-1 plasma levels have shown to predict advanced disease state and to a lesser extent worst prognosis. Any increase in sPD-1 plasma level post therapeutically have been correlated with improved survival for various cancers. In vitro and in vivo studies have shown sPD-1 ability to bind PD-L1 and PD-L2 and block PD-1/PD-L1 interaction. Local delivery of sPD-1 in cancer tumor microenvironment through local gene therapy have demonstrated an increase in tumor specific CD8+ T cell immunity and tumor growth reduction. It had also exhibited enhancement of T cell immunity induced by vaccination and other gene therapeutic agents. Furthermore, it may also lessen the inhibitory effect of circulating sPD-L1 and enhance the effects of mAb-based immunotherapy. In this review, we highlight various aspects of sPD-1 role in cancer prediction, prognosis, and anti-cancer immunity, as well as, its therapeutic value for local gene therapy or systemic immunotherapy in blocking the PD-1 and PD-L1 checkpoint interactions.

soluble programmed cell death protein 1 local gene therapy cancer vaccination prediction prognosis immune checkpoint blockade

SCI

英语

第一 ; 通讯

Natural Science Foundation of Shenzhen[JCYJ20170307095828424] ; Shenzhen Health and Family Planning System Research Project[SZBC2017024] ; technical research and cultivation project for the youth of Shenzhen People's Hospital[SYKYPY2019029]

Immunology

Immunology

WOS:000595891300001

FRONTIERS MEDIA SA

Web of Science

1.Southern Univ Sci & Technol, Dept Radiat Oncol, Shenzhen Peoples Hosp, Affiliated Hosp 1, Shenzhen, Peoples R China
2.Anhui Med Univ, Dept Oncol, Affiliated Hosp 1, Hefei, Peoples R China
3.Jinan Univ, Dept Nephrol, Shenzhen Peoples Hosp, Second Clin Med Ctr, Shenzhen, Peoples R China
4.Univ Sialkot, Dept Biochem, Sialkot, Pakistan

Khan, Muhammad,Zhao, Zhihong,Arooj, Sumbal,et al. Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy[J]. Frontiers in Immunology,2020,11.

Khan, Muhammad,Zhao, Zhihong,Arooj, Sumbal,Fu, Yuxiang,&Liao, Guixiang.(2020).Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.Frontiers in Immunology,11.

Khan, Muhammad,et al."Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy".Frontiers in Immunology 11(2020).